Factors related to depression and anxiety in adults with bronchiectasis

Elif Yelda Özgün
Niksarlioglu¹
Gülcihan Özkan²
Gülşah Günlüoğlu¹
Mehmet Atilla Uysal¹
Sule Gül¹
Lütfiye Kilic¹
Ayse Yeter¹
Güngör Çamsarı¹

¹Department of Chest Disease, Yedikule Chest Disease and Thoracic Surgery Training and Research Hospital, ²Department of Chest Disease, Yenyüzyıl University Gaziosmanpaşa Hospital, Istanbul, Turkey

Introduction and background: Patients with chronic lung diseases frequently have depressive and anxiety symptoms, but there are very few studies looking at this in patients with bronchiectasis.

Aim: This study aimed to investigate depression and anxiety and related factors among patients with non-cystic fibrosis bronchiectasis.

Patients and methods: This was a prospective study of 133 patients with bronchiectasis. Patients with confirmed diagnosis of bronchiectasis with high-resolution computed tomography were enrolled in the study. Patients that were clinically stable in the previous 4 weeks were evaluated with the Hospital Depression and Anxiety scale. Symptoms, pulmonary function tests, and medical treatments were recorded.

Results: The mean age of patients was 49.5±14.5 years (range, 18–77 years), and 81 (60.9%) patients were females. Twenty-eight (21.1%) patients had depression, and 53 (39.8%) had anxiety. Depression score was related to family situation (living with a partner), previous depression history and admission to an emergency department within the last year. Anxiety score was related to female gender, the family situation (living with a partner), previous depression history, and admission to an emergency department within the last year ($P<0.05$). Depression was positively correlated with hemoptysis, admission to an emergency department within the last year and living with a partner. Anxiety was positively correlated with education level, previous depression history, admission to an emergency department within the last year, and living with a partner.

Conclusion: Patients with non-cystic fibrosis bronchiectasis are at increased risk for depression and anxiety. Untreated and undetected depressive/anxiety symptoms may increase physical disability, morbidity, and health care utilization. It is important for clinicians to be aware of the presence of depression and anxiety in bronchiectasis.

Keywords: anxiety, bronchiectasis, depression, risk factor

Introduction

Bronchiectasis is defined as irreversible, abnormal dilatation of one or more bronchi with chronic airway inflammation and results in a chronic cough, sputum production, recurrent chest infection, and airflow obstruction.^{1,2} According to US data, the estimated prevalence of bronchiectasis is 53 cases per 100,000 adults.³ Seitz et al reported that prevalence of bronchiectasis was 1,106 cases per 100,000 people.⁴ The prevalence increases with age and is higher in females. As it is a chronic disease, bronchiectasis may lead to a decrease in exercise capacity and cause difficulty in performing daily living activities.

Ryu et al reported that depression and anxiety are more prevalent in subjects with chronic airway diseases, and this is associated with low quality of life and impaired

Correspondence: Elif Yelda Özgün
Niksarlioglu
Department of Chest Disease, Yedikule
Chest Disease and Thoracic Surgery
Training and Research Hospital, Belgrad
kapi yolu street no 1, Zeytinburnu,
Istanbul, Turkey
Tel +90 212 409 0200
Fax +90 212 547 2233
Email eyelda2003@yahoo.com

adherence to therapy.⁵ Similarly, although psychiatric disorders such as anxiety and depression are related to worsened respiratory symptoms, increased health expenditure, and noncompliance with therapy in the patients with chronic pulmonary diseases, it may frequently be overlooked in daily practice.^{6,7} There are a limited number of studies on the prevalence of depression and anxiety in either pediatric or adult cases with bronchiectasis, which is a significant chronic pulmonary problem.^{8–10}

In the present prospective study, we aimed to investigate the presence of depression and anxiety in outpatients with non-cystic fibrosis bronchiectasis using the Hospital Anxiety Depression scale. In addition, we evaluated the relationship between sociodemographic, clinical factors and depression and anxiety in adult patients with bronchiectasis.

Patients and methods

A total of 133 patients with stable bronchiectasis who were diagnosed using high-resolution computed tomography (HRCT) enrolled to the study. Cases with cystic fibrosis, malignancy, interstitial pulmonary disease on HRCT and acute exacerbation of bronchiectasis were excluded. An acute exacerbation was defined as having at least three of the following criteria: worsened dyspnea and coughing, an increase in the amount and purulence of sputum, hemoptysis, fever ($\geq 38^{\circ}\text{C}$), worsening in clinical examination, and the presence of new signs on a chest X-ray. Demographic data, body mass index, marital status, education, occupation, smoking status, and comorbidity status were recorded for all patients. In addition, clinical characteristics of the patients, medications, the use of nebulizers (nebulizer is used for inhaled betamimetic and/or inhaled steroid drugs) and long-term oxygen therapy (LTOT; long-term oxygen therapy is extended use of oxygen; oxygen therapy is delivered as a gas from an oxygen source like concentrator), number of emergency and hospital admissions and intensive care stays within the last year, and pulmonary function tests were recorded.

After clinical and radiological examination, Hospital Anxiety Depression Scale (HADS) was performed on the stable patients. HADS was developed in 1983 by Zigmond and Snaith, and validity and reliability were performed.¹¹ HADS questionnaire is a test consisting of 14 questions, of which seven are used to assess depression and the remaining seven are used to assess anxiety. The answers were evaluated in the form of four-point Likert-type scale. The scale was scored between 0 (best) and 3 (worst). Total score ranges between 0 and 21 points. While the cutoff value is 7 for

depression, it is 10 for anxiety in the Turkish version. Validation of the Turkish version of the test was done in 1997.¹²

The study protocol was approved by the Local Ethics and Clinical Research Committee of the Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital. All participants gave written informed consent.

Statistical analyses

Statistical analyses were carried out using SPSS Statistics for Windows, version 20.0 (IBM Corporation, Armonk, NY, USA). Descriptive data were presented as mean $\pm$ standard deviation, and median (range), when there is not a normal distribution. The univariate analyses to identify variables associated with patient outcome according to the HADS scores (anxiety and depression) was investigated using chi-square and Fisher exact tests. For the multivariate analysis, the possible factors identified with univariate analyses were further entered into the logistic regression analysis to determine independent predictor of patient outcome. Hosmer–Lemeshow goodness of fit statistics were used to assess model fit. A 5% type-I error level ($P < 0.05$) was used to interpret statistical significance.

Results

A total of 133 patients with bronchiectasis were enrolled in this study. The mean age of patients was 49.5 ± 14.5 years (range, 18–77 years), and 81 (60.9%) of the patients were females. The mean diagnosed time of the study group was 6.8 ± 4 years (range, 1 month–30 years). The baseline characteristics of the 133 patients are shown in Table 1.

The clinical symptoms of the patients included in this study are summarized in Table 1. No statistically significant difference was found between the groups with high and low depression and anxiety scores regarding symptoms (cough, sputum, dyspnea, and hemoptysis) ($P > 0.05$). Concerning medical therapies, 111 (83.5%) were receiving bronchodilators, 17 (12.8%) were using nebulizers, and 14 (10.5%) were on LTOT. When comparing medical therapy for bronchiectasis and HAD scale scores, no statistically significant difference was found between the groups ($P > 0.05$). Furthermore, no relationship was found between the use of a nebulizer, LTOT and depression and anxiety ($P > 0.05$).

The mean HADS score was 10.9 ± 8.3 ; the mean depression score was 4.8 ± 4.3 , and the mean anxiety score was 6.1 ± 4.7 . The cutoff point for depression and anxiety was taken as 7 and 10, respectively, and therefore, 28 (21.1%) patients had depression, and 53 (39.8%) had anxiety. Depression score was related to the family situation (living

Table 1 Demographic characteristics of patients

Variables	Results (n=133)*
Age (years)	49.5±14.5
Female	81 (60.9)
Male	52 (39.1)
Smoking habit	
Nonsmoker	76 (65.3)
Active smoker	45 (33.8)
Ex-smoker	12 (9)
Family situation	
With partner/other family member	108 (81.2)
Live alone	21 (18.8)
Level of education	
<8 years	84 (63.1)
≥8 years	49 (36.9)
Employment	68 (51.1)
Unemployed	65 (48.9)
Comorbidity**	41 (34.6)
No comorbidity	87 (65.4)
History of depression	42 (31.6)
History of anxiety	13 (9.8)
FEV ₁ ,%	62.2 (23.8)
FVC,%	68.2 (21.2)
FEV ₁ /FVC	71.7 (13.8)
Symptoms	
Cough	109 (82)
Dyspnea	102 (76.7)
Sputum	77 (57.9)
Hemoptysis	40 (30.1)
Admission to emergency department within the last year	65 (48.9)
Hospitalization	20 (15)

Notes: *Data are shown as: n (%) or X ± SD. **Hypertension, diabetes mellitus, coronary arterial disease, or gastroesophageal reflux.

Abbreviations: SD, standard deviation; FEV₁, forced expiratory volume 1 second; FVC, forced vital capacity.

without a partner), previous depression history and admission to the emergency department within the last year. Anxiety score was related to female gender, employment, family situation (living without a partner), previous depression history, and admission to the emergency department within the last year (Table 2).

The first stepwise multivariate model for depression was performed which included the variables: age, gender, family situation, comorbidity, hospitalization, admission to an emergency department within the last year, and history of depression and anxiety. This model showed that living with a partner (odds ratio [OR] 0.17695, 95% confidence interval [CI]: 0.459–0.675, $P=0.011$) and admission to the emergency department in last year (OR 4.236, 95% CI: 1.277–14.0522, $P=0.018$) were independently related to depression. When the symptoms were added to the model, only hemoptysis (OR 0.255, 95% CI: 0.687–0.948, $P=0.041$) was a significant predictor of high scores of depression

(Table 3). However, pulmonary function tests did not affect the risk of depression in adults with bronchiectasis.

The multivariate model was performed including age, gender, employment, family situation, comorbidity, admission to the emergency department within the last year, hospitalization within the last year, and history of anxiety and depression for anxiety. This analysis identified four variables related to increased risk for clinically relevant anxiety: living with a partner (OR 0.075, 95% CI: 0.015–0.358, $P=0.001$), education level (<8 years) (OR 7.613, 95% CI: 1.514–3.2570, $P=0.014$), admission to emergency department within the last year (OR 3.177, 95% CI: 1.041–9.695, $P=0.04$), and history of depression (OR 7.170, 95% CI: 2.317–22.1847, $P=0.001$) (Table 4). When symptoms and/or pulmonary function tests were added to the analysis, none of the symptoms were independent risk factors for anxiety, with living with a partner, education level (<8 years), admission to an emergency department within the last year and history of depression remaining significant.

Discussion

In the present study, we found that depression and anxiety ratios were high in adults with bronchiectasis, similar to that found in previous studies.^{8,9} Clinically significant depression was associated with living with a partner, admission to the emergency department within the last year and hemoptysis. These parameters were independent risk factors for depression with bronchiectasis. Also, anxiety was significantly associated with living with a partner, education level (<8 years), previous depression history and admission to the emergency department within the last year.

Today, depression and anxiety are an important health problem in both developed and developing countries. According to data from the World Health Organization, the prevalence of depression ranges from 3% to 16.9%.¹³ Despite the availability of studies on the prevalence of depression and anxiety and the related risk factors in chronic respiratory diseases, particularly in COPD, there is a limited number of studies published on the prevalence of depression and anxiety in adult patients with bronchiectasis.^{5,14,15} A limited number of previous studies in the literature reported a higher prevalence of depression and anxiety in bronchiectasis cases in comparison to general population.^{8,9} Olveria et al reported depression symptoms in 12.68% and anxiety symptoms in 18% of bronchiectasis cases evaluated by the HADS.⁹

Girón Moreno et al in their article published in 2013, reported depression in 34% and trait and state anxiety in 55% of non-cystic fibrosis bronchiectasis cases. They indicated

Table 2 Factors associated with depression and anxiety in patients with bronchiectasis

	HAD-D			HAD-A		
	<7	≥7	P-values	<10	≥10	P-values
Number	105 (78.9)	28 (21.1)		80 (60.2)	53 (39.8)	
Age, years	49.6±14.5	48.7±14.5	>0.05	50.8±14.1	47.9±14.9	>0.05
Female	61 (45.8)	20 (15)	>0.05	41 (30.8)	40 (30.1)	0.005
Male	44 (33.1)	8 (6)		39 (29.3)	13 (9.8)	
Smoking						
Never smoker	60 (45.5)	17 (12.9)	>0.05	44 (33.3)	33 (25)	>0.05
Ever smoker	44 (33.3)	11 (8.3)		35 (26.5)	20 (15.2)	
Employment	48 (37.5)	17 (13.3)	>0.05	33 (25.8)	32 (25)	0.028
Nonemployment	52 (40.6)	11 (8.6)		44 (34.4)	19 (14.8)	
Family situation						
Live alone	23 (17.3)	12 (9)	< 0.05	10 (7.5)	15 (11.3)	0.022
With partner/other family member	92 (69.2)	16 (12)		70 (52.6)	38 (28.6)	
No history of depression	76 (57.1)	15 (11.3)	0.05	65 (48.9)	26 (19.5)	< 0.05
History of depression	29 (21.8)	13 (9.8)		15 (11.3)	27 (20.3)	
PFTs						
FEV ₁ , % predicted	63.9 (24.5)	56.1 (20.6)	>0.05	64.1 (23.8)	59.5 (23.8)	>0.05
FVC, % predicted	68.9 (21.1)	65.7 (21.7)	>0.05	69.1 (21.1)	67.1 (21.4)	>0.05
FEV ₁ /FVC	72.3 (14.4)	69.8 (11.3)	>0.05	72.1 (13.2)	71.2 (14.6)	>0.05
No admission to an emergency department	59 (44.4)	9 (6.8)	0.023	47 (35.3)	21 (15.8)	0.031
Admission to an emergency department	46 (34.6)	19 (14.3)		33 (24.8)	32 (24.1)	
No hospitalization	89 (66.9)	24 (18)	>0.05	69 (51.9)	44 (33.1)	>0.05
Hospitalization	16 (12)	4 (3)		11 (8.3)	9 (6.8)	

Notes: Data presented as mean ± SD or n (%). Cutoff point for depression is 7 points and 10 points for anxiety. Statistically significant parameters are shown as a bold value. **Abbreviations:** HAD-A, hospital anxiety depression scale-anxiety; HAD-D, hospital anxiety depression scale-depression; PFTs, pulmonary functions; FEV₁, forced expiratory volume 1 second; FVC, forced vital capacity.

that depressive symptoms were more prevalent in females and that anxiety was associated with the daily amount of sputum and presence of bacterial colonization in the sputum.⁸ In the present patient population, female gender was associated with anxiety; however, no relationship was found between the amount of sputum and depression and anxiety. A study on patients with COPD, which is also a chronic airway disease, assessed depression, anxiety, pain, and quality of life and reported more severe anxiety and depression and poorer quality of life in the female patient group.¹⁶ Most of

the earlier studies indicate female gender as an independent risk factor for depression and anxiety.

In the present study, investigating the relationship between respiratory symptoms and depression and anxiety in bronchiectasis cases, we found that only hemoptysis was an independent risk factor for depression, while anxiety was not associated with any of the symptoms. Goldbeck et al found that hemoptysis and recurrent pneumothorax were associated with anxiety, whereas impaired pulmonary function tests and being a lung transplant candidate were

Table 3 Predictive factors for depression in patients with bronchiectasis

Factors	OR (95% CI)	P-values
Age	1.010 (0.964–1.058)	0.654
Male gender	1.172 (0.349–3.927)	0.797
Live with a partner	0.176 (0.459–0.675)	0.011
Comorbidity	0.692 (0.201–2.382)	0.560
Depression history	2.521 (0.842–7.549)	0.098
Panic disorder history	2.372 (0.737–7.637)	0.148
Admission to an emergency department	4.236 (1.277–14.0522)	0.018
Panic disorder history	1.932 (0.433–8.627)	0.148
Hospitalization	0.426 (0.768–2.309)	0.388
Hemoptysis	0.255 (0.687–0.948)	0.041

Note: Statistically significant parameters are shown as a bold value. **Abbreviations:** OR, odds ratio; CI, confidence interval.

Table 4 Logistic regression analysis for elevated symptoms for anxiety in patients with bronchiectasis

Factors	OR (95% CI)	P-values
Age	1.000 (0.950–1.047)	0.988
Male gender	0.421 (0.140–1.125)	0.124
Education, <8 years	7.613 (1.514–3.2570)	0.014
Live with a partner	0.075 (0.015–0.358)	0.001
Depression history	7.170 (2.317–22.1847)	0.001
Panic disorder history	2.625 (0.415–16.5713)	0.305
Comorbidity	0.619 (0.184–2.077)	0.438
Admission to emergency department	3.177 (1.041–9.695)	0.042
Hospitalization	0.637 (0.113–3.591)	0.610

Note: Statistically significant parameters are shown as a bold value. **Abbreviations:** OR, odds ratio; CI, confidence interval.

associated with depression in 670 patients with cystic fibrosis aged between 12 and 64 years.¹⁷ Hemoptysis is a common and distressing symptom in bronchiectasis cases, particularly during exacerbations. For this reason, recurrent hemoptysis, in particular, may promote depressive mood despite the fact that we failed to determine any relationship with anxiety.

Various studies have reported a relationship between age and depression and/or anxiety. Oliveira et al investigated depression and anxiety symptoms and health-related quality of life in 93 bronchiectasis cases.⁶ In this study, age was found to be associated with both depression and anxiety. Likewise, another study reported that the prevalence of anxiety and depression increases but the quality of life decreases with age.⁹ This may result from the fact that the disease becomes chronic and loss of respiratory functions and comorbidities accompany the disease with aging. In the present study, however, we determined no relationship between age and depression and anxiety. This may have resulted from a limited number of cases.

In the recent study, Oliveira et al evaluated the relationship between depression/anxiety symptoms and quality of life in bronchiectasis patients.⁶ Oliveira et al determined depression symptoms in 20% and anxiety symptoms in 38% of bronchiectasis cases and found that the amount of sputum was associated with depression, whereas exacerbation was an association with anxiety. In another study by Oliveira et al, the number of exacerbations in the previous year was found to be higher in bronchiectasis cases with anxiety.⁶ In our study, the prevalence of anxiety and depression was as high as in the study by Oliveira et al.⁶ However, we questioned the number of emergency room admissions and hospital stays within the last year, but we did not ask history of exacerbations. While hospital stay was not associated with depression or anxiety, emergency room admissions within the year was determined to be an independent risk factor for anxiety and depression. A study investigating the depression-related factors in COPD, chronic airway diseases like bronchiectasis reported that emergency room admissions and hospital stay were more frequent in cases with depression but exacerbations were not significantly high.¹⁵ In the present study, patients were inquired for emergency room admissions for respiratory problems within the last year, but whether these were exact exacerbations of bronchiectasis was not investigated.

There is strong evidence that a presence of anxiety and depression in cases with chronic respiratory diseases such as bronchiectasis impairs adherence to therapy and reduces

patients quality of life.^{9,16,18} In the present study, however, adherence to therapy or quality of life was not assessed, although we inquired the patients about their medication use. Considering particularly the fact that adherence to therapy was associated with the frequency of exacerbations and survival, identification and treatment of anxiety and depression gain more importance. We think that prospective studies are needed on this subject.

Some studies have investigated the relationship between pulmonary function tests (FEV₁, FVC, and FEV₁/FVC ratio) and depression and anxiety. Particularly in COPD, FEV₁ and FVC are considered to be the risk factors for depression.^{5,15} Girón Moreno et al conducted a study in cases with non-cystic fibrosis bronchiectasis and found no significant relationship between FEV₁ and depression or anxiety.⁸ Like Girón Moreno et al,⁸ in Oliveira et al's study there was no relationship between FEV₁ and depression or anxiety in patients with bronchiectasis.⁹

In the study by O'Leary et al, no relationship was found between FEV₁ and HADS scores.¹⁹ Likewise, the present study found no relationship between FEV₁, FVC, FEV₁/FVC and depression and anxiety. This may be related to the limited number of cases and/or differences in the extent of disease on HRCT.

Living with a partner has been found as an independent risk factor for both depression and anxiety. Moreover, anxiety symptoms increase with lower education levels. Oliveira et al reported a similar result about education level.⁶ It is difficult to explain why living with a partner is associated with depression and anxiety. Evaluation of the partner may give some idea for this association.

Our study has some limitations. Increasing the number of patients enrolled in the study could rise the intensity. Furthermore, patients with high depression and anxiety scores were not referred to psychiatric evaluation.

Conclusion

In conclusion, patients with non-cystic fibrosis bronchiectasis are at increased risk for anxiety and depression. Admission to an emergency department within the last year and living with a partner were related to depression and anxiety. Also, hemoptysis was correlated with depression, and education level, previous depression history was associated to anxiety. Untreated and undetected depressive and anxiety symptoms may increase physical disability, morbidity, and health care utilization. Future research is needed to address the impact, early detection, and management of anxiety and depression from bronchiectasis.

Disclosure

The authors declare no conflicts of interest in this work.

References

1. Chan ED, Iseman MD. Bronchiectasis. In: Broaddus VC, Mason RJ, Ernst JD, King TE, Lazarus SC, Murray JF, Nadel JA, Slutsky A, Gotway M, editors. *Murray & Nadel's Textbook of Respiratory Medicine*, 6th ed. Canada: Saunders Ltd; 2016:853–876.
2. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. *Eur Respir J*. 2015;45(5):1446–1462.
3. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. *Clin Pulm Med*. 2005;12(4):205–209.
4. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. *Chest*. 2012;142(2):432–439.
5. Ryu YJ, Chun EM, Lee JH, Chang JH. Prevalence of depression and anxiety in outpatients with chronic airway lung disease. *Korean J Intern Med*. 2010;25(1):51–57.
6. Oliveira C, Oliveira G, Gaspar I, et al. Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life. *Qual Life Res*. 2013;22(3):597–605.
7. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. *Gen Hosp Psychiatry*. 2007;29(2):147–155.
8. Girón Moreno RM, Fernandes Vasconcelos G, Cisneros C, Gómez-Punter RM, Segrelles Calvo G, Ancochea J. Presence of anxiety and depression in patients with bronchiectasis unrelated to cystic fibrosis. *Arch Bronchoneumol*. 2013;49(10):415–420.
9. Oliveira C, Oliveira G, Espildora F, et al. Mediterranean diet is associated on symptoms of depression and anxiety in patients with bronchiectasis. *Gen Hosp Psychiatry*. 2014;36(3):277–283.
10. Bahali K, Gedik AH, Bilgic A, et al. The relationship between psychological symptoms, lung function and quality of life in children and adolescents with non-cystic fibrosis bronchiectasis. *Gen Hosp Psychiatry*. 2014;36(5):528–532.
11. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatrica Scand*. 1983;67(6):361–370.
12. Aydemir Ö, Güvenir T, Küey S, Kültür S. Turkish version validation of hospital anxiety and depression scale. *Turkish J Psychiatry*. 1997;8:280–287. Turkish.
13. Marcus M, Yasamy MT, Ommeren Mv, Chisholm D, Saxena S. *Depression: a global public health concern*. WHO department of mental health and substance abuse. Available from: www.who.int/mental_health/management/depression. Accessed October 8, 2016.
14. Wagena EJ, Arrindell WA, Wouters EF, van Schayck CP. Are patients with COPD psychologically distressed? *Eur Respir J*. 2005;26(2):242–248.
15. Martinez Rivera C, Costan Galicia J, Alcázar Navarrete B, et al. Factor associated with depression in COPD: a multicenter study. *Lung*. 2016;194(3):335–343.
16. Di Marco F, Verga M, Reggente M, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. *Respir Med*. 2006;100(10):1767–1774.
17. Goldbeck L, Besier T, Hinz A, Singer S, Quittner AL, TIDES Group. Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis. *Chest*. 2010;138(4):929–936.
18. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. *Med Care*. 2002;40(9):794–811.
19. O'Leary CJ, Wilson CB, Hansell DM, Cole PJ, Wilson R, Jones PW. Relationship between psychological well-being and lung health status in patients with bronchiectasis. *Respir Med*. 2002;96(9):686–692.

Neuropsychiatric Disease and Treatment

Dovepress

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS,

and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>